Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-alkyl ethylbenzyl dimethyl ammonium (C12-C14) is a quaternary ammonium compound with surfactant and antimicrobial properties. It is widely used as an active ingredient in sanitizing solutions, soaps, and disinfecting cleaning products due to its broad-spectrum activity against gram-positive and gram-negative bacteria, some fungi, and certain viruses. The mechanism of action involves irreversible binding to the phospholipids and proteins of microbial cell membranes, impairing membrane permeability. This leads to disruption or dissociation of the lipid bilayer in bacterial cells, resulting in leakage of cellular contents and cell death. Systemic absorption through intact human skin is minimal; thus, systemic effects are rare when used topically[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-alkyl ethylbenzyl dimethyl ammonium (C12-C14).